Literature DB >> 24871642

Prevalence of antibody to Bordetella pertussis in neonates and prevalence of recent pertussis infection in pregnant women in Catalonia (Spain) in 2003 and 2013.

Pedro Plans1, Elena Álvarez, Fernando de Ory, Magda Campins, Toni Payà, Pilar Balfagón, Pere Godoy, Joan Caylà, Ramon Carreras, Lluís Cabero, Angela Domínguez.   

Abstract

BACKGROUND: Infections because of Bordetella pertussis still occur in infants and adults in European countries, despite vaccination coverage against pertussis being high.
METHODS: IgG antibody titers to pertussis toxin (anti-PT) were assessed using an enzyme-linked immunosorbent assay test (Serion ELISA classic) in 353 cord blood samples from neonates of a representative sample of pregnant women obtained in Catalonia (Spain) in 2013. Neonates with anti-PT titers ≤ 40 international units (IU)/mL were considered to be unprotected against pertussis. IgG-PT titers >100 IU/mL in umbilical cord samples were considered to be indicative of a current or recent pertussis infection (12 months) in pregnant women. The age-standardized prevalence of recent pertussis infection obtained in this study was compared with the prevalence obtained in 2003.
RESULTS: The mean anti-PT titer in neonates was 10.8 IU/mL and 89.8% of neonates were unprotected against pertussis. The prevalence of unprotected neonates as defined by cord blood anti-PT ≤ 40 IU/mL was 90%. The prevalence of recent pertussis infection in pregnant women as defined by cord blood anti-PT >100 IU/mL was 2%. The diphtheria-tetanus-pertussis vaccination coverage during childhood in pregnant women was 75%. The age-standardized prevalence of recent pertussis infection in pregnant women observed in this study (2.2%) was slightly higher than the prevalence obtained in 2003 (1.5%), with an odds ratio = 1.45 (95% confidence intervals: 0.5-3.9), although differences were not statistically significant.
CONCLUSIONS: Most neonates are unprotected against pertussis and pertussis infections are frequent in pregnant women in Catalonia. Infants and pregnant women should be the priority population groups for pertussis prevention programs in Catalonia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24871642     DOI: 10.1097/INF.0000000000000413

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Clinical characteristics and pertussis costs in cases reported to epidemiological services and cases detected in household contacts in Catalonia (Spain).

Authors:  P Plans; C Muñoz-Almagro; P Godoy; M Jané; G Carmona
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-30       Impact factor: 3.267

2.  Factors influencing the spread of pertussis in households: a prospective study, Catalonia and Navarre, Spain, 2012 to 2013.

Authors:  Pere Godoy; Manuel García-Cenoz; Diana Toledo; Glòria Carmona; Joan A Caylà; Miquel Alsedà; Josep Àlvarez; Irene Barrabeig; Neus Camps; Pere Plans; María Company; Jesús Castilla; Maria-Rosa Sala-Farré; Carmen Muñoz-Almagro; Cristina Rius; Àngela Domínguez
Journal:  Euro Surveill       Date:  2016-11-10

3.  Antibodies to Bordetella pertussis antigens in maternal and cord blood pairs: a Thai cohort study.

Authors:  Nasamon Wanlapakorn; Thanunrat Thongmee; Preeyaporn Vichaiwattana; Elke Leuridan; Sompong Vongpunsawad; Yong Poovorawan
Journal:  PeerJ       Date:  2017-11-23       Impact factor: 2.984

4.  Seroprevalence of diphtheria and pertussis immunoglobulin G among children with pneumonia in Ji'nan, China.

Authors:  Qinghong Meng; Lijun Li; Wei Shi; Qing Wang; Mingjie Ding; Yanqin Liu; Xiang Ma; Kaihu Yao
Journal:  BMC Pediatr       Date:  2018-12-05       Impact factor: 2.125

5.  Seroprevalence of Maternal and Cord Antibodies Specific for Diphtheria, Tetanus, Pertussis, Measles, Mumps and Rubella in Shunyi, Beijing.

Authors:  Qing-Hong Meng; Ying Liu; Jin-Qian Yu; Li-Jun Li; Wei Shi; Ying-Jie Shen; Li Li; Shi-Na Zhan; Fan Yang; Ya-Juan Wang; Kai-Hu Yao
Journal:  Sci Rep       Date:  2018-08-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.